Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2017-05-29 Director's Dealing
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
DGAP-DD: BB BIOTECH AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section labeled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Klaus Strein), their position (Member of the administrative or supervisory body), the nature of the transaction ('Acquisition'), the financial instrument (Share), and the date and price of the transaction. This content directly matches the definition for Director's Dealing.
2017-05-29 English
DGAP-DD: BB BIOTECH AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed sections regarding 'Details of the person discharging managerial responsibilities' (a director) and 'Details of the transaction(s)', specifically noting an 'Allocation from a Board of Directors share-based remuneration program'. This content directly matches the definition for Director's Dealing reports.
2017-04-24 English
BB Biotech reports pleasing quarterly results
Earnings Release Classification · 100% confidence The document is explicitly titled 'Interim Report of BB Biotech AG as of March 31, 2017' and contains detailed financial performance metrics (bottom-line profit of CHF 375 mn), portfolio activity, and market commentary for the first quarter of 2017. This structure and content align perfectly with the definition of a comprehensive financial report for a period shorter than a year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Although it mentions the AGM, the primary focus is the quarterly financial results. Q1 2017
2017-04-21 English
Q1 statement / Q1 financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at March 31, 2017' and contains comprehensive financial data, including a multi-year comparison, consolidated interim financial statements, and detailed management commentary on portfolio performance and strategy. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-04-21 German
BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 2.75 (news with additional features)
AGM Information Classification · 99% confidence The document text explicitly mentions 'Shareholders at the general meeting vote in favor of all proposals and approve the dividend'. It also contains the keyword 'AGM/EGM' in the DGAP header. The content details the results of the Annual General Meeting (AGM), including the approval of board members and the dividend payout. This strongly indicates the document is related to the AGM results. The most specific category for AGM results and voting outcomes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it relates to the AGM (AGM-R), DVA specifically covers the *results* of the shareholder vote, which is the primary focus here.
2017-03-16 English
BB BIOTECH AG: Annual report 2016 (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is titled 'BB BIOTECH AG: Annual report 2016 (news with additional features)' and explicitly states, 'BB Biotech AG publishes its 2016 annual report'. It contains key financial highlights (net loss, NAV decline, total return) for the fiscal year ending December 31, 2016, and mentions the audited consolidated financial statements are contained within the report. Although it discusses the content of the Annual Report (10-K equivalent for non-US companies, but often classified similarly or as a comprehensive IR document), the format is a 'Media release' disseminated via DGAP, which typically serves as an announcement or summary. However, the content is comprehensive enough to be considered the primary disclosure of the annual results, rather than just a brief announcement of publication. Given the detailed financial figures and the explicit mention of the 'annual report' being published, it strongly aligns with the content expected in an Annual Report (10-K). Since the document is relatively long (5378 chars) and contains the core results, it is classified as the report itself, which for a non-US entity reporting full year results is best mapped to the comprehensive '10-K' category, or potentially 'IR' if it were purely an investor summary, but the reference to audited statements points towards the formal annual filing.
2017-02-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.